There’s a 75%-off sale on Macy’s stock. Is this a going out of business sale?
Will this pharmaceutical giant be able to grow through Celgene’s patent cliff? Perhaps not, but it's still worth an investment.
This pharmaceutical giant is a victim of its own success. Will an $86 billion acquisition stave off its impending patent cliff?
The networking gear giant released disappointing guidance. Is this weak outlook an industry phenomenon or is it more company-specific?
Is the recent closing of the Red Hat acquisition reaccelerating Big Blue’s growth?
Altria remains strong despite tobacco industry transformation.
AT&T's latest earnings report and the unveiling of HBO Max should reassure investors this behemoth is heading in the right direction.
The hysteria surrounding the vaping industry has neared its apogee and the overreaction will soon correct itself.
The potential merger between cigarette makers has been called off. So how does Philip Morris stand alone as an investment?